Qimudesiren, Chen SN, Qian LR. Human leukocyte antigen and donor-specific antibodies in liver transplantation. World J Gastroenterol 2025; 31(2): 101620 [DOI: 10.3748/wjg.v31.i2.101620]
Corresponding Author of This Article
Li-Ren Qian, MD, Senior Department of Hematology, The Fifth Medical Center of PLA General Hospital, No. 8 Dongda Street, Haidian District, Beijing 100071, China. qlr2007@126.com
Research Domain of This Article
Transplantation
Article-Type of This Article
Letter to the Editor
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Gastroenterol. Jan 14, 2025; 31(2): 101620 Published online Jan 14, 2025. doi: 10.3748/wjg.v31.i2.101620
Human leukocyte antigen and donor-specific antibodies in liver transplantation
Qimudesiren, Sha-Na Chen, Li-Ren Qian
Qimudesiren, School of Clinical Medicine, Inner Mongolia Minzu University, Tongliao 028000, Inner Mongolia Autonomous Region, China
Sha-Na Chen, Department of Hematology, International Mongolian Hospital of Inner Mongolia, Hohhot 010065, Inner Mongolia Autonomous Region, China
Li-Ren Qian, Senior Department of Hematology, The Fifth Medical Center of PLA General Hospital, Beijing 100071, China
Li-Ren Qian, The Second School of Clinical Medicine, Southern Medical University, Guangzhou 510515, Guangdong Province, China
Co-corresponding authors: Sha-Na Chen and Li-Ren Qian.
Author contributions: Qimudesiren contributed to manuscript drafting and writing; Chen SN contributed to critical revision; Qian LR contributed to conception and design.
Conflict-of-interest statement: The authors report no relevant conflicts of interest for this article.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Li-Ren Qian, MD, Senior Department of Hematology, The Fifth Medical Center of PLA General Hospital, No. 8 Dongda Street, Haidian District, Beijing 100071, China. qlr2007@126.com
Received: September 20, 2024 Revised: October 26, 2024 Accepted: November 21, 2024 Published online: January 14, 2025 Processing time: 88 Days and 14.6 Hours
Abstract
In this article, we comment on an article published in a recent issue of the World Journal of Gastroenterology. We specifically focus on the roles of human leukocyte antigen (HLA) and donor-specific antibodies (DSAs) in pediatric liver transplantation (LT), as well as the relationship between immune rejection after LT and DSA. Currently, LT remains the standard of care for pediatric patients with end-stage liver disease or severe acute liver failure. However, acute and chronic rejection continues to be a significant cause of graft dysfunction and loss. HLA mismatch significantly reduces graft survival and increases the risk of acute rejection. Among them, D→R one-way mismatch at three loci was significantly related to graft-versus-host disease incidence after LT. The adverse impact of HLA-DSAs on LT recipients is already established. Therefore, the evaluation of HLA and DSA is crucial in pediatric LT.
Core Tip: Donor-specific antibodies (DSAs), particularly those against human leukocyte antigen (HLA) DQ loci, significantly affect rejection risk and graft survival in pediatric liver transplantation. The presence of DSAs is linked to increased rates of both acute and chronic rejection, which impacts long-term graft viability. These findings highlight the importance of improved HLA and DSA monitoring and management to improve long-term outcomes in pediatric liver transplant recipients.
